Non-small cell lung cancer (NSCLC) represents the leading cause of death for cancer (1). In 2004, for the first time Lynch et al. demonstrated that a subgroup of NSCLC patients (10–15%), harboring somatic mutations in the epidermal growth factor receptor (EGFR) gene, showed sensitivity and clinical benefit to a novel class of drugs targeting the tyrosine kinase domain; the so called tyrosine kinase inhibitors (TKIs).
Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: Are the available data convincing? / Malapelle, U.; Rossi, A.; Bria, E.. - In: JOURNAL OF THORACIC DISEASE. - ISSN 2072-1439. - 11:Suppl 15(2019), pp. S1837-S1840. [10.21037/jtd.2019.08.99]
Relationship between performance status or younger age and osimertinib therapy in T790M-positive NSCLC: Are the available data convincing?
Malapelle U.;
2019
Abstract
Non-small cell lung cancer (NSCLC) represents the leading cause of death for cancer (1). In 2004, for the first time Lynch et al. demonstrated that a subgroup of NSCLC patients (10–15%), harboring somatic mutations in the epidermal growth factor receptor (EGFR) gene, showed sensitivity and clinical benefit to a novel class of drugs targeting the tyrosine kinase domain; the so called tyrosine kinase inhibitors (TKIs).I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.